Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:1.16.3.1 (ceruloplasmin)
 5,074 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We previously identified 9 genes (i.e., thymosin beta4, secreted protein acidic and rich in cysteine, Cap43, ceruloplasmin, serum amyloid A, heat shock protein 90, LOT1, osteopontin and casein kinase Igamma) that are more highly expressed in cancerous regions than in noncancerous regions in human renal cancers. In our study, we considered the possibility that the von Hippel-Lindau (VHL) tumor suppressor gene might be able to affect the expression of these 9 genes in renal cancer cells. We first established 2 VHL-positive cell lines, 786/VHL-1 and 786/VHL-2, after the introduction of wild-type VHL into VHL-negative renal cancer 786-O cells. Of these 9 genes, expression of the Cap43 gene was specifically downregulated by VHL. Expression of Cap43 was also much lower in 4 other VHL-positive renal cancer cell lines than in VHL-negative 786-O cells. Cap43 promoter assays with several deletion or mutation constructs demonstrated that the Sp1 site in the element from -286 base pairs (bp) to -62 bp was partly responsible for VHL-induced suppression of the Cap43 gene. Immunostaining analysis with human specimens of renal cancers demonstrated that the Cap43 protein was expressed in most cancer cells and macrophages. We also observed a marked and specific increase of Cap43 mRNA levels in response to hypoxia or nickel in all VHL-positive cell lines. Cellular expression of Cap43 mRNA in response to hypoxia or nickel thus is closely associated with VHL gene expression in renal cancer cells. Although the function of the Cap43 protein remains unclear, the expression of Cap43 protein could be a molecular marker closely associated with VHL in renal cancer.
 ...
PMID:Downregulation of Cap43 gene by von Hippel-Lindau tumor suppressor protein in human renal cancer cells. 1276 66

The electron paramagnetic resonance (EPR) technique was used to study the venous blood levels of Fe(3+)-transferrin (Fe(3+)-TF) and Cu(2+)-ceruloplasmin (Cu(2+)-CP) in three different groups: donors, outpatients, and patients with Stages I-IV bladder and kidney cancer. The anemia-related range of concentrations of paramagnetic centers Fe(3+)-TF was determined, which corresponded to the hemoglobin levels below the normal physiological value (< or = 120 g/l). It was found that the blood concentration of Cu(2+)-TCP exceeded the normal value in the donors and outpatients who had anemia whereas it increased up to abnormally high values in anemic cancer virtually always due to the enhanced synthesis of CP. Simultaneous monitoring of Fe(3+)-TF and Cu(2+)-CP levels may serve as a basis for the rapid diagnosis of cancers by the technique EPR even in the early stage of the tumor process. The method may be also used to predict the course of the disease and to screen anemic patients.
 ...
PMID:[The abilities of the electron paramagnetic resonance technique to diagnose urological cancers]. 2157 57

Changes in Fe(3+)-transferrin (Fe(3+)-Tf) and Cu(2+)-ceruloplasmin (Cu(2+)-Cp) concentrations in venous blood sampled from anemic patients with urinary bladder and kidney cancer in I-IV stages were investigated using electron paramagnetic resonance spectroscopy. It was established that at malignancy-associated anemia the paramagnetic Fe3+ ion concentration in transferrin is below a norm, while in anemic non-oncology patients the Tf iron saturation is normal. Moreover, in patients with malignancy-associated anemia the Cu(2+)-Cp average value is nearly twice as large as that for healthy volunteers (confidence probability P). It was shown that simultaneous EPR measuring of paramagnetic centers (such as Fe(3+)-Tf and Cu(2+)-Cp) in blood of anemic patients can be used as a biomarker for urological cancer diagnosis even at early stages of the growth of a malignant tumor.
 ...
PMID:[Electron paramagnetic resonance study of blood of anemic patients with urological cancer]. 2375 56